Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Ramipril Treatment of Claudication

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02842424
Recruitment Status : Unknown
Verified October 2018 by Iraklis I Pipinos, MD, University of Nebraska.
Recruitment status was:  Recruiting
First Posted : July 22, 2016
Last Update Posted : October 31, 2018
Sponsor:
Information provided by (Responsible Party):
Iraklis I Pipinos, MD, University of Nebraska

Brief Summary:
Peripheral artery disease (PAD) is a manifestation of atherosclerosis that produces progressive narrowing and occlusion of the arteries supplying the lower extremities. The most common clinical manifestation of PAD is claudication, i.e., a severe functional limitation identified as gait dysfunction and walking-induced leg muscle pain relieved by rest. The standard therapies for claudication include the medications cilostazol and pentoxifylline, supervised exercise therapy and operative revascularization. Recent data demonstrated that 24 weeks of treatment with the angiotensin-converting enzyme (ACE) inhibitor Ramipril produces improvements in the walking performance of patients with claudication that are higher than those of cilostazol and pentoxifylline and similar to those produced by supervised exercise therapy and operative revascularization. The mechanisms by which Ramipril therapy produces this impressive improvement in the functional capacity of claudicating patients remain unknown. The Investigators hypothesize that treatment of claudicating PAD patients with Ramipril will improve walking performance and quality of life by improving the myopathy of the gastrocnemius. Improved myopathy is a consequence of reduced oxidative damage, reduced TGF-β1 production by vascular smooth muscle cells and reduced collagen deposition in the affected gastrocnemius.

Condition or disease Intervention/treatment Phase
Peripheral Arterial Disease Drug: Ramipril Phase 4

Detailed Description:

This is an interventional study of PAD patients that exhibit claudication. The purpose of this study is to determine the potential mechanisms by which Ramipril vastly improves the walking performance of these patients. The study will be achieved through these specific aims:

Specific Aim #1: Test the hypothesis that Ramipril-mediated improvements of walking parameters among patients with PAD correlate with improvements in both the morphometrics and biochemistry of myofibers in the gastrocnemius of the impaired limb.

Specific Aim #2: Test the hypothesis that Ramipril-mediated improvements of walking parameters in patients with PAD correlate with reduced fibrotic events in small vessels and microvasculature, in association with reduced generalized collagen deposition and improved tissue oxygenation, in the gastrocnemius of the impaired limb.

Specific Aim #3: Using adult human arterial smooth muscle cells (AHASMC), in vitro, the Investigators will test the hypothesis that the ACE inhibitor Ramipril, which acts as an antagonist of Angiotensin II type 1 receptor (ART1) stimulation by reducing tissue Angiotensin II (Ang II), impedes a mechanism in which Ang II stimulation of ART1 and exposure to hypoxia enhance proliferation of AHASMC and their production of TGF-β1 and collagen, via stimulation of phosphoinositide-3-kinase signaling and suppression of phosphatase and tensin homologue, a master regulator of cell growth.

If the above hypotheses are correct, Aims #1 and #2 will demonstrate for the first time that therapy with Ramipril improves the walking performance and quality of life of claudicating PAD patients by improving the myopathy in skeletal muscle of the ischemic lower limbs. The work in Aim #3 will determine the pathways by which hypoxia and Angiotensin II cooperate to induce myopathy in the ischemic muscle. Specific agents targeting these pathways could become new treatments for claudication and for the more advanced stages of PAD characterized by leg rest pain and gangrene.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 70 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Ramipril Treatment of Claudication: Oxidative Damage and Muscle Fibrosis
Study Start Date : October 2015
Estimated Primary Completion Date : March 2020
Estimated Study Completion Date : March 31, 2020

Resource links provided by the National Library of Medicine

Drug Information available for: Ramipril

Arm Intervention/treatment
Experimental: Ramipril Treatment
6 months treatment with the medication Ramipril
Drug: Ramipril
Ramipril therapy will start at 2.5mg/day for 1 week. Then 5mg/day for 1 week and will be increased to 10mg/day by the third week. The patients will stay on Ramipril 10mg/day for 22 weeks.




Primary Outcome Measures :
  1. Absolute Claudication Distance [ Time Frame: 6 months ]
    Maximum walking distance in meters per Gardner protocol


Secondary Outcome Measures :
  1. 6-minute Walking Distance [ Time Frame: 6 months ]
    Maximum Distance in meters the patient can walk in 6 minutes on a flat, hard surface

  2. Initial Claudication Distance [ Time Frame: 6 months ]
    The distance in meters the patient can walk before he experiences claudication pain, per Gardner protocol

  3. Average Daily Steps Taken [ Time Frame: 6 months ]
    Monitored with an accelerometer at home

  4. Quality of life measured by the Walking Impairment Questionnaire [ Time Frame: 6 months ]
  5. Quality of life measured by the Medical Outcomes Study Short Form 36 Healthy Survey [ Time Frame: 6 months ]
  6. Leg biomechanics measured as Vertical ground reaction force [ Time Frame: 6 months ]
  7. Leg hemodynamics measured as Ankle Brachial Index (ABI) [ Time Frame: 6 months ]
    Ratio of the blood pressure at the level of the ankle to the blood pressure at the level of the arm

  8. Leg hemodynamics measured as Calf blood flow via contrast-enhanced ultrasound [ Time Frame: 6 months ]
  9. Leg hemodynamics measured as Calf blood flow via stress ABI testing [ Time Frame: 6 months ]
  10. Leg hemodynamics measured as Calf muscle hemoglobin oxygen saturation [ Time Frame: 6 months ]
    Measured with Near Infrared Spectroscopy

  11. Myofiber Mitochondrial Respiration, measured by polarography [ Time Frame: 6 months ]
  12. Muscle Mitochondrial Function, measured by spectrophotometry [ Time Frame: 6 months ]
  13. Myofiber Oxidative Damage [ Time Frame: 6 months ]
    Myofiber content of HNE adducts and protein carbonyls

  14. Myofiber Morphology, Cross-Sectional Area [ Time Frame: 6 months ]
    Area in square microns, measured by immunofluorescence microscopy

  15. Myofiber Morphology, Roundness [ Time Frame: 6 months ]
    Measured as ratio of major axis in microns to minor axis in microns

  16. Myofiber Morphology, Solidity [ Time Frame: 6 months ]
    Measured as the ratio of myofiber area in square microns to the area of a fitted convex hull in square microns

  17. Muscle Fibrosis, Muscle TGF-β1 [ Time Frame: 6 months ]
    Measured as the sum of the products of mean pixel intensity (in gray scale units) and area (in square microns) of each TGF-β1 labeled event divided by the total area (in square microns) of the tissue sample analyzed. Measured by immunofluorescence microscopy.

  18. Muscle Fibrosis, Total collagen deposited. [ Time Frame: 6 months ]
    Measured as the area-weighted mean pixel intensity (in gray scale units) of all the collagen labeled events per tissue sample. Measured by bright-field microscopy.

  19. Microvascular Fibrosis, Capillary wall thickness. [ Time Frame: 6 months ]
    Measured in microns by immunofluorescence microscopy of vessels labeled for collagen.

  20. Capillary density. [ Time Frame: 6 months ]
    Number of capillaries per unit area (in square microns) of the tissue sample analyzed.

  21. Serum biomarker of fibrosis, serum procollagen type I c-peptide in picograms of peptide per ml [ Time Frame: 6 months ]
  22. Serum biomarker of fibrosis, serum procollagen type III n-terminal peptide in picograms of peptide per ml [ Time Frame: 6 months ]
  23. Plasma biomarker of fibrosis, plasma TGF-β1 in picograms per ml [ Time Frame: 6 months ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 90 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. A positive history of chronic claudication,
  2. Exercise-limiting claudication established by history and direct observation during a screening walking test administered by the evaluating vascular surgeon,
  3. Arterial occlusive disease per ankle Brachial index measurements and/or other imaging modalities,
  4. Stable blood pressure regimen, stable lipid regimen, stable diabetes regimen and risk factor control for 6 weeks.

Exclusion Criteria:

  1. Rest pain or tissue loss due to PAD (Fontaine stage III and IV),
  2. acute lower extremity ischemic event secondary to thromboembolic disease or acute trauma,
  3. Walking capacity significantly limited by conditions other than claudication including leg (joint/musculoskeletal, neurologic) and systemic (heart, lung disease) pathology,
  4. Current use of either ACE inhibitors or angiotensin II receptor blockers,
  5. Chronic kidney disease with estimated Glomerular Filtration Rate < 30 ml/min/1.73 m2,
  6. History of bilateral severe renal artery stenosis and 7) History of angioedema related to previous ACE-inhibitor treatment or known hypersensitivity to ramipril or other ACE inhibitors.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02842424


Contacts
Layout table for location contacts
Contact: Holly DeSpiegelaere 402-995-4171 Holly.DeSpiegelaere@va.gov
Contact: Neha K Woods, PhD 402-559-5540 neha.woods@unmc.edu

Locations
Layout table for location information
United States, Nebraska
VA Medical Center Recruiting
Omaha, Nebraska, United States, 68105
Contact: Holly DeSpiegelaere    402-995-4171    Holly.DeSpiegelaere@va.gov   
Sponsors and Collaborators
University of Nebraska
Investigators
Layout table for investigator information
Principal Investigator: Iraklis I Pipinos, MD University of Nebraska
Principal Investigator: George P Casale, PhD University of Nebraska
Layout table for additonal information
Responsible Party: Iraklis I Pipinos, MD, Professor of Surgery, University of Nebraska
ClinicalTrials.gov Identifier: NCT02842424    
Other Study ID Numbers: 139-16-ET
00991 ( Other Identifier: VAMC-IRB )
First Posted: July 22, 2016    Key Record Dates
Last Update Posted: October 31, 2018
Last Verified: October 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Keywords provided by Iraklis I Pipinos, MD, University of Nebraska:
Ramipril
Angiotensin-converting enzyme
Claudication
Myopathy
Peripheral Arterial Disease
Additional relevant MeSH terms:
Layout table for MeSH terms
Peripheral Arterial Disease
Peripheral Vascular Diseases
Intermittent Claudication
Atherosclerosis
Arteriosclerosis
Arterial Occlusive Diseases
Vascular Diseases
Cardiovascular Diseases
Ramipril
Angiotensin-Converting Enzyme Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antihypertensive Agents